Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Strikes Deals with Bayer, Lilly; Hires Vuko

Premium

P

ALO ALTO, Calif.--Incyte Pharmaceuticals won another LifeSeq subscriber last week and expanded its licensing arrangement with an existing subscriber. In a new deal, Bayer subscribed to the LifeSeq Gold database for therapeutic protein discovery, gaining access to Incyte’s portfolio of more than 50,000 genes. Incyte did not reveal terms of the deal, and said only that it could receive future milestone payments and royalties on product sales.

Meanwhile, Eli Lilly, which already subscribed to the LifeSeq Gold product, extened its agreement to become the first subscriber to Incyte’s database of single-nucleotide polymorphisms.

Separately, Incyte has hired John Vuko as its new CFO to replace Denise Gilbert who resigned last year. Vuko had previously been CFO at Achievement Radio Holdings and Ross Stores, and held various positions with the Cooper family of companies.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.